The results, presented at SABCS this week, leave open whether the added benefit from chemo seen in premenopausal women may be due to chemo-induced hormone reduction.
Genentech will use Adaptive's ClonoSeq assay for MRD testing in a CLL study. Adaptive will receive upfront and sample testing payments of undisclosed amounts.
